125 related articles for article (PubMed ID: 24823632)
1. Tumor-promoting inflammatory networks in pancreatic neoplasia: another reason to loathe Kras.
Vonderheide RH
Cancer Cell; 2014 May; 25(5):553-4. PubMed ID: 24823632
[TBL] [Abstract][Full Text] [Related]
2. Cancer: Targeting IL-17 in pancreatic cancer.
Cully M
Nat Rev Drug Discov; 2014 Jul; 13(7):493. PubMed ID: 24981357
[No Abstract] [Full Text] [Related]
3. Oncogenic Kras activates a hematopoietic-to-epithelial IL-17 signaling axis in preinvasive pancreatic neoplasia.
McAllister F; Bailey JM; Alsina J; Nirschl CJ; Sharma R; Fan H; Rattigan Y; Roeser JC; Lankapalli RH; Zhang H; Jaffee EM; Drake CG; Housseau F; Maitra A; Kolls JK; Sears CL; Pardoll DM; Leach SD
Cancer Cell; 2014 May; 25(5):621-37. PubMed ID: 24823639
[TBL] [Abstract][Full Text] [Related]
4. Nicotine promotes initiation and progression of KRAS-induced pancreatic cancer via Gata6-dependent dedifferentiation of acinar cells in mice.
Hermann PC; Sancho P; Cañamero M; Martinelli P; Madriles F; Michl P; Gress T; de Pascual R; Gandia L; Guerra C; Barbacid M; Wagner M; Vieira CR; Aicher A; Real FX; Sainz B; Heeschen C
Gastroenterology; 2014 Nov; 147(5):1119-33.e4. PubMed ID: 25127677
[TBL] [Abstract][Full Text] [Related]
5. Oncogenic Kras-induced GM-CSF production promotes the development of pancreatic neoplasia.
Pylayeva-Gupta Y; Lee KE; Hajdu CH; Miller G; Bar-Sagi D
Cancer Cell; 2012 Jun; 21(6):836-47. PubMed ID: 22698407
[TBL] [Abstract][Full Text] [Related]
6. Oncogenic KRAS Induces NIX-Mediated Mitophagy to Promote Pancreatic Cancer.
Humpton TJ; Alagesan B; DeNicola GM; Lu D; Yordanov GN; Leonhardt CS; Yao MA; Alagesan P; Zaatari MN; Park Y; Skepper JN; Macleod KF; Perez-Mancera PA; Murphy MP; Evan GI; Vousden KH; Tuveson DA
Cancer Discov; 2019 Sep; 9(9):1268-1287. PubMed ID: 31263025
[TBL] [Abstract][Full Text] [Related]
7. RAGE is essential for oncogenic KRAS-mediated hypoxic signaling in pancreatic cancer.
Kang R; Hou W; Zhang Q; Chen R; Lee YJ; Bartlett DL; Lotze MT; Tang D; Zeh HJ
Cell Death Dis; 2014 Oct; 5(10):e1480. PubMed ID: 25341034
[TBL] [Abstract][Full Text] [Related]
8. Critical role of oncogenic KRAS in pancreatic cancer (Review).
Liu J; Ji S; Liang C; Qin Y; Jin K; Liang D; Xu W; Shi S; Zhang B; Liu L; Liu C; Xu J; Ni Q; Yu X
Mol Med Rep; 2016 Jun; 13(6):4943-9. PubMed ID: 27121414
[TBL] [Abstract][Full Text] [Related]
9. Oncogenic KRAS activates hedgehog signaling pathway in pancreatic cancer cells.
Ji Z; Mei FC; Xie J; Cheng X
J Biol Chem; 2007 May; 282(19):14048-55. PubMed ID: 17353198
[TBL] [Abstract][Full Text] [Related]
10. Trisomy of the Dscr1 gene suppresses early progression of pancreatic intraepithelial neoplasia driven by oncogenic Kras.
Lee JC; Shin J; Baek KH
Biochem Biophys Res Commun; 2013 Oct; 440(1):50-5. PubMed ID: 24041692
[TBL] [Abstract][Full Text] [Related]
11. Requirement of NEMO/IKKγ for effective expansion of KRAS-induced precancerous lesions in the pancreas.
Maier HJ; Wagner M; Schips TG; Salem HH; Baumann B; Wirth T
Oncogene; 2013 May; 32(21):2690-5. PubMed ID: 22751123
[TBL] [Abstract][Full Text] [Related]
12. Disruption of p16 and activation of Kras in pancreas increase ductal adenocarcinoma formation and metastasis in vivo.
Qiu W; Sahin F; Iacobuzio-Donahue CA; Garcia-Carracedo D; Wang WM; Kuo CY; Chen D; Arking DE; Lowy AM; Hruban RH; Remotti HE; Su GH
Oncotarget; 2011 Nov; 2(11):862-73. PubMed ID: 22113502
[TBL] [Abstract][Full Text] [Related]
13. Activation Of Wild-Type Hras Suppresses The Earliest Stages Of Pancreatic Cancer.
Weyandt J
Redox Biol; 2015 Aug; 5():414. PubMed ID: 28162272
[TBL] [Abstract][Full Text] [Related]
14. Co-dependency between KRAS addiction and ARHGEF2 promotes an adaptive escape from MAPK pathway inhibition.
Kent OA; Sandi MJ; Rottapel R
Small GTPases; 2019 Nov; 10(6):441-448. PubMed ID: 28656876
[TBL] [Abstract][Full Text] [Related]
15. KRAS(G12D)- and BRAF(V600E)-induced transformation of murine pancreatic epithelial cells requires MEK/ERK-stimulated IGF1R signaling.
Appleman VA; Ahronian LG; Cai J; Klimstra DS; Lewis BC
Mol Cancer Res; 2012 Sep; 10(9):1228-39. PubMed ID: 22871572
[TBL] [Abstract][Full Text] [Related]
16. KRas, ROS and the initiation of pancreatic cancer.
Storz P
Small GTPases; 2017 Jan; 8(1):38-42. PubMed ID: 27215184
[TBL] [Abstract][Full Text] [Related]
17. Oncogenic Kras maintains pancreatic tumors through regulation of anabolic glucose metabolism.
Ying H; Kimmelman AC; Lyssiotis CA; Hua S; Chu GC; Fletcher-Sananikone E; Locasale JW; Son J; Zhang H; Coloff JL; Yan H; Wang W; Chen S; Viale A; Zheng H; Paik JH; Lim C; Guimaraes AR; Martin ES; Chang J; Hezel AF; Perry SR; Hu J; Gan B; Xiao Y; Asara JM; Weissleder R; Wang YA; Chin L; Cantley LC; DePinho RA
Cell; 2012 Apr; 149(3):656-70. PubMed ID: 22541435
[TBL] [Abstract][Full Text] [Related]
18. Oncogenic Kras is required for both the initiation and maintenance of pancreatic cancer in mice.
Collins MA; Bednar F; Zhang Y; Brisset JC; Galbán S; Galbán CJ; Rakshit S; Flannagan KS; Adsay NV; Pasca di Magliano M
J Clin Invest; 2012 Feb; 122(2):639-53. PubMed ID: 22232209
[TBL] [Abstract][Full Text] [Related]
19. Oncogenic KRAS and the EGFR loop in pancreatic carcinogenesis-A connection to licensing nodes.
Schneeweis C; Wirth M; Saur D; Reichert M; Schneider G
Small GTPases; 2018 Nov; 9(6):457-464. PubMed ID: 27880072
[TBL] [Abstract][Full Text] [Related]
20. KRAS promotes tumor metastasis and chemoresistance by repressing RKIP via the MAPK-ERK pathway in pancreatic cancer.
Yang K; Li Y; Lian G; Lin H; Shang C; Zeng L; Chen S; Li J; Huang C; Huang K; Chen Y
Int J Cancer; 2018 Jun; 142(11):2323-2334. PubMed ID: 29315556
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]